FORM 51-102F3
MATERIAL CHANGE REPORT

ITEM 1 Name and Address of Company:

EastWest Bioscience Inc.
410 – 885 Dunsmuir Street
Vancouver, British Columbia V6C 1N5

ITEM 2 Date of Material Change:

January 9, 2019.

ITEM 3 News Release:

A news release was distributed via Accesswire and filed via the System for Electronic Document Analysis and Retrieval ("**SEDAR**") website at www.sedar.com on January 9, 2019.

ITEM 4 Summary of Material Change:

EastWest Bioscience Inc. (the "**Company**" or "**EastWest**") (TSXV: EAST) announced that Mr. Paul Marjerrison, B. Comm., CPA, CA, has been appointed Chief Financial Officer of the Company.

ITEM 5 Full Description of Material Change:

5.1 – Full Description of Material Change:

Reference is made to the press release attached hereto.

5.2 – Disclosure for Restructuring Transactions:

Not applicable.

ITEM 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102:

Not Applicable.

ITEM 7 Omitted Information:

Not Applicable.

ITEM 8 Executive Officer:

Further information relating to this Material Change Report may be obtained from:

Rodney Gelineau
Co-Founder, Chief Executive Officer, President and Director
Telephone: (647) 394-7383

ITEM 9 Date of Report:

DATED as of January 19, 2019.

EastWest Announces Appointment of New Chief Financial Officer

Vancouver, British Columbia – January 9, 2019 – EastWest Bioscience Inc. (the "**Company**" or "**EastWest**") (TSXV: EAST) is pleased to announce that Mr. Paul Marjerrison, B. Comm., CPA, CA, has been appointed Chief Financial Officer of the Company. In 2018, Mr. Marjerrison assisted EastWest with its acquisition of Sangster's Health Centres, including pre-closing diligence, the purchase and sale agreement, and post-closing integration, as well as financial planning, analysis and reporting for EastWest. Since 2015, Mr. Marjerrison has owned and operated a financial management business, working as a contract Chief Financial Officer or financial advisor for several clients. From 2011 to 2015, Mr. Marjerrison worked with a mid-market corporate finance firm, assisting clients with divestitures, acquisitions, debt financings and exempt market capital raises. Prior to 2011, Mr. Marjerrison worked in public practice with a national accounting firm, focusing on audit engagements. Mr. Marjerrison has a Bachelor of Commerce in finance and accounting from the University of Saskatchewan.

Mr. Marjerrison succeeds Mr. Geoff Balderson who has resigned as Chief Financial Officer of the Company to pursue his other business interests. The Company would like to thank Mr. Balderson for his service to the Company.

About EastWest BioScience Group

EastWest Bioscience is a seed-to-sale organization that offers world class manufacturing and premium hemp-based consumer goods. Since it was founded in 2016, EastWest continues to grow as a high-quality producer, manufacturer and distributor of multiple lines of premium hemp products. EastWest is strategically positioned in mainstream consumer markets with wholistic natural products and has developed distribution channels into mainstream stores and markets in Canada. The Company has a Health Canada licensed, GMP (Good Manufacturing Practices) certified manufacturing facility and produces premium brands offering natural products for a preventive care lifestyle. EastWest consumer product lines are divided into four distinct brands: 1) Natural Advancement – natural biopharmaceutical health supplements; 2) Earth's Menu – all-natural hemp superfoods; 3) Natural Pet Science – pet food and pet supplements; and 4) Chanvre Hemp – all-natural health and beauty products. The organization will continue to focus on ongoing development of innovative, hemp-based consumer products through advanced science with clean, natural ingredients to complement its current product offerings.

ON BEHALF OF THE BOARD OF DIRECTORS
EASTWEST BIOSCIENCE GROUP

"Rodney Gelineau"
Co-Founder, Chief Executive Officer, President and Director

For further information, please visit www.eastwestbioscience.com or contact EastWest Bioscience Investor Relations at 1-647-394-7383 or email us at investors@eastwestscience.com.

Reader Advisory

This news release may contain statements which constitute "forward-looking information", including statements regarding the plans, intentions, beliefs and current expectations of the Company, its directors, or its officers with respect to the future business activities of the Company. The words "may", "would", "could", "will", "intend", *"plan", "anticipate", "believe", "estimate", "expect" and similar expressions, as they relate to the Company, or its management, are intended to identify such forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future business activities and involve risks and uncertainties, and that the Company's future business activities may differ materially from those in the forward-looking statements as a result of various factors, including, but not limited to, fluctuations in market prices, successes of the operations of the Company, continued availability of capital and financing and general economic, market or business conditions. There can be no assurances that such information will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. The Company does not assume any obligation to update any forward-looking information except as required under the applicable securities laws.*

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.